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Abstract
Introduction: The mechanism of pathogenesis of pituitary adenomas is still unknown, and it shows differences in pituitary cells of dif-
ferent origin.
The aim of our study was to analyse the gene expression profile of pituitary hormones and their precursor genes: PRL, GH, POMC, TSHb, 
LHb, FSHb, and CGA by QPCR in particular types of pituitary adenomas, and to evaluate the results in the context of sample selection 
for microarray studies.
Material and methods: Analysis of the gene expression profile was performed in 84 samples of pituitary adenomas, by real-time quantita-
tive PCR (QPCR). 
Results: As expected, expression of GH gene was significantly higher in somatotropinomas than in prolactinomas (p<0.05). For POMC 
gene we noticed lower expression in all pituitary adenomas, except adrenocorticotropinomas (p<0.05). In the case of PRL gene, the high-
est expression was observed; PRL+ adenomas were in third place. LHb and FSHb genes showed the highest expression, respectively, in 
LH-producing and FSH-producing pituitary adenomas; however, our analysis did not show statistically significant differences between 
LH-producing and FSH-producing adenomas. 
Conclusions: Our study showed that GH is a characteristic gene for somatotropinomas. We drew a similar conclusion for POMC gene 
and adrenocorticotropinomas.
However, the results that we obtained for PRL, TSHb, LHb, FSHb, and CGA genes indicate that evaluation of gene expression is not suf-
ficient for classification of particular subtypes of pituitary adenomas. (Endokrynol Pol 2016; 67 (2): 148–156)
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Streszczenie
Wstęp: Mechanizm odpowiedzialny za patogenezę gruczolaków przysadki nie został jeszcze w pełni wyjaśniony i wykazuje różnice 
w różnych typach komórek przysadki.
Celem badania była analiza profilu ekspresji genów kodujących hormony przysadkowe i ich prekursory: PRL, GH, POMC, TSHb, LHb, 
FSHb, CGA w poszczególnych typach gruczolaków przysadki oraz ocena uzyskanych wyników w kontekście wyboru próbek do badań 
mikromacierzowych.
Materiał i metody: Analizę ekspresji genów przeprowadzono za pomocą ilościowej reakcji PCR w czasie rzeczywistym (QPCR) na ma-
teriale 84 gruczolaków przysadki. 
Wyniki: Ekspresja genu GH była znamiennie wyższa w gruczolakach somatotropinowych (GH+) w porównaniu z prolaktynowymi (PRL+). 
Zaobserwowano również wzrost ekspresji tego genu w guzach GH+ w stosunku do gruczolaków immunohistochemicznych ujemnych. 
Dla genu POMC wykazano niską ekspresję we wszystkich badanych grupach gruczolaków, z wyjątkiem gruczolaków kortykotropino-
wych (ACTH+). Najwyższą ekspresję genu PRL zaobserwowano w gruczolakach somatotropinowych; gruczolaki prolaktynowe były 
na trzecim miejscu. Dla genów LHb i FSHb nie zaobserwowano statystycznie znamiennych różnic pomiędzy gruczolakami LH+ i FSH+.
Wnioski: W niniejszym badaniu potwierdzono, że gen GH jest charakterystyczny dla gruczolaków somatotropinowych, podobnie jak 
gen POMC dla gruczolaków kortykotropinowych. Jednakże, wyniki uzyskane dla genów PRL, TSHb, LHb, FSHb i CGA wskazują, że ocena 
ekspresji  genów nie jest wystarczająca dla prawidłowej klasyfikacji poszczególnych podtypów gruczolaków przysadki. 
(Endokrynol Pol 2016; 67 (2): 148–156)
Słowa kluczowe: gruczolak przysadki; ekspresja genu; QPCR
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Pituitary tumours are relatively frequent intracranial 
tumors and constitute a very interesting model: they 
share the properties of well-differentiated endocrine 
tumors, which are able to secrete hormones, characteristic 
for the cell of origin and the ability for invasive growth, 
characteristic for neoplastic cells [1]. Among pituitary 
adenomas there is a wide variety of phenotypes: from 
hormone-producing tumours to non-functioning 
adenomas. Most functioning pituitary adenomas secrete 
prolactin (~40%) [2–4], about 20% secrete growth hor-
mone [5], ~10% secrete corticotropin [1, 3], ~10–15 % 
secrete glycoprotein hormones (LH, FSH) [1], and less 
than 1% secrete thyrotropin [6]. The other pituitary ad-
enomas (~5%) are negative for hormone secretion, and 
these are referred to as immunohistochemically nega-
tive (null adenomas) [7]. Pituitary tumours have been 
classified in different ways. The oldest classification was 
based on cellular characteristics using haematoxylin and 
eosin stains on resected tissues; however, this classifi-
cation did not take into account clinical symptoms or 
hormone production by the adenoma. With the advent 
of immunohistochemical tests, tumours are now clas-
sified according to the characteristic hormone staining 
and electron microscopic changes. This classification is 
in general agreement with the reported clinical signs 
and symptoms. Currently, this is the main way to dis-
tinguish different types of pituitary tumours. However, 
it is expected that in the future, molecular and genetic 
techniques will also be applied. At the present time, 
microarray studies are a powerful method for global 
analysis of gene expression profile, opening up new 
horizons in molecular systems. In the case of pituitary 
adenomas there is still little specific knowledge about 
the gene expression profile differentiating particular 
subtypes of pituitary tumours. 
In our study we focused on one of the crucial 
steps of microarray studies: sample selection. For this 
purpose, we used real-time quantitative PCR (QPCR), 
which is the most common method for fast, accurate, 
sensitive, and cost-effective gene expression analysis in 
many samples concurrently. It generates high-quality 
data without the requirement of additional validation, 
and it is applied to validate data obtained by higher 
throughput technologies such as microarray. 
The main goal of our study was to analyse the gene 
expression profile of pituitary hormones and their 
precursor genes: PRL, GH, POMC, TSHb, LHb, FSHb 
and CGA by QPCR in particular types of pituitary 
adenomas, and to evaluate the results in the context of 
sample selection for microarray studies.
Material and methods
The study was approved by the Ethics Committee 
of Maria Sklodowska-Curie MSC Cancer Centre and 
Institute of Oncology in Gliwice. 
Patients
The studied group of consisted of 84 patients operated 
on for pituitary adenoma with application of endoscop-
ic transnasal transsphenoidal approach (ETTA) in the 
Department of Neurosurgery of the Medical University 
of Silesia, Poland. There were 41 women and 43 men. 
The mean age was 53.2 years (18–70 years) for the fe-
male subgroup and 52.7 years (20–77 years) for men. In 
10 cases, tumours had increased features of invasiveness, 
i.e. the presence of tumour cells in samples of dura ob-
tained during the surgery, in histopathological examina-
tion. Moreover, all aforementioned tumours infiltrated 
lateral walls of the sella, so they were classified as III or 
IV degree in Knosp’s Classification of Cavernous Sinus 
Invasion. In six cases surgical resection was performed 
as a reoperation. In all of the aforementioned six cases 
surgery was the first reoperation. 
Tumours
The analysis of gene expression was performed in 
84 samples of pituitary adenomas, collected with the 
cooperation of the Department of Neurosurgery of the 
Silesian Medical University in Katowice. Fragments 
of pituitary adenomas were taken intraoperatively 
and stored in RNA at 4°C. All adenomas were histo-
pathologically verified. As judged by postoperative 
immunohistochemistry (IHC), there were 13 GH+, 
26 PRL+, 8 ACTH+, 5TSH+, 11 LH+, 5 FSH+ and 
16 null adenomas (with negative immunohistochemistry 
toward the previous hormones). The percentage of 
TSH-positive adenomas in the study group was rela-
tively high compared to published data; however, we 
collected so many tumours intentionally because we 
wanted to analyse the gene expression level also in 
rare functional pituitary adenomas. Moreover, using 
a smaller group of TSH+ pituitary adenomas in statistical 
analysis might have led to biased results in this analysis.
The GH+, PRL+, ACTH+ and TSH+ adenomas 
were grouped as functional adenomas (FA) due to the 
clinical symptoms caused, while LH+, FSH+, and null 
adenomas were described clinically as non-functioning 
tumours (NFA).
Isolation of RNA
Total RNA was extracted from homogenised frozen tis-
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RNA quantity was measured by NanoDrop ND-1000 
(Thermo Scientific, Wilmington, DE, USA) minispectro-
photometer, and the quality was estimated by Agilent 
2100 using RNA 6000 Nano Assay (Agilent Technologies, 
Santa Clara, CA, USA). RNA integrity, assessed by RIN 
index, was within the 4.5–9.1 range.
cDNA synthesis
cDNA was synthesised from 500 ng of total RNA by 
Omniscript Kit (Qiagen GmbH, Hilden, Germany), with 
a mixture of oligo-dT and random nonamer primers 
(Sigma-Aldrich, ST. Louise, USA) and 10U RNAse in-
hibitor (Fermentas Thermo Fisher Scientific, Walthman, 
USA). The reaction was carried out at 37ºC for one hour. 
Quantitative real-time reverse transcription-PCR 
(QPCR)
Analysis of gene expression was performed by real-time 
quantitative PCR with the use of fluorescent probes from 
the Universal Probe Library (Roche, Basel, Switzerland). 
Amplicons were designed using a web-based application 
(www.roche-applied-science.com/sis/rtpcr/upl) (Table I). 
QPCR was carried out in a 96-well optical reaction plate 
using an ABI Prism 7700 Sequence Detection System 
(Applied Biosystems). Five microlitres of template cDNA 
(equivalent to 500 ng of total RNA) were added to 15 µl 
of PCR reaction mix containing 10 µl TaqMan Universal 
PCR Master Mix (Life Technologies, Carlsbad, CA, USA), 
1 µl forward and reverse primers (200 nM), 1 µl probe 
(100 nM), and water. Thermal cycling condition were as 
follows: 50°C for two minutes (incubation and activation 
AmpErase UNG), 95°C for 10 minutes (activation Ampl-
iTag Polymerase DNA), 95°C for 15 seconds (denatura-
tion), and 60°C for one minute (annealing and extension). 
Every sample was examined in duplicate. The standard 
curve, used in experiments, was prepared from serial 
dilutions of human reference RNA (Stratagene, La Jolla, 
CA, USA). Expression of the examined genes was nor-
malised to the reference index, obtained by calculation 
of the geometric mean of the reference genes expression: 
ACTB, EIF3S10, ATP6V1E, UBE2D2, B2M, and GUS B.
Statistical analysis
geNorm application software for Microsoft Excel was 
used to identify the most stable reference gene under 
the described conditions, and to determine the optimal 
number of reference genes required for reliable nor-
malisation of QPCR data.
Table I. Amplicons used for quantitative real-time PCR measurement of analysed genes
Tabela I. Sekwencje starterów i sondy do ilościowej reakcji PCR dla genów badanych oraz genów kontrolnych
Gene Name Gene ID Primer F  sequence Primer R  sequence Probe Probe  sequence
Investigated genes
PRL Prolactin NM_000948.2 AAAGGATCGCCATGGAAAG GCACAGGAGCAGGTTTGAC 18 TCCTGCTG
GH Growth hormone NM_000515.3 CCAACAGGGAGGAAACACAA GACACTCCTGAGGAACTGCAC 19 GGCTGGAG
POMC Proopiomelanocortin NM_000939.2 CAGGAGAGCTCGGCAAGTAT GGCTCTTCTTCCCCTCCTT 82 CTCCTCTG
TSHb Thyroid-stimulating 
hormone, beta subunit
S70587.1 CAGCACAATGGATACGCATAA CAGCACAATGGATACGCATAA 33 TCCCAGCTC
FSHb Follicle-stimulating hormone, 
beta polypeptide
NM_000510.2 TGGTGTGCTGGCTACTGCT CCTTGAAGGTACATGTTTTCTGG 20 CTGGCTGG
LHb Luteinizing hormone, beta 
polypeptide
NM_000894.2 GCTACTGCCCCACCATGA GCTACTGCCCCACCATGA 71 CTGGCTGC
CGA Glycoprotein hormones, 
alpha polypeptide
NM_000735.2 TCTCCATTCCGCTCCTGAT GGGAGAAGAATGGGTTTTCC 61 TTGCCCAG
Reference genes
ACTB b-actin NM_001101.2 ATTGGCAATGAGCGGTTC GGATGCCACAGGACTCCAT 11 CTTCCAGC
ATP6V1E1 ATPase, H+ transporting, 
lysosomal 31kDa,  
V1 subunit E1
NM_001696.2 AAGCCGGCTGGATCTCAT GCATTTGCACCAAACAAGG 3 CCCAGCAG
B2M b-2-microglobulin NM_004048.2 TTCTGGCCTGGAGGCTATC TCAGGAAATTTGACTTTCCATTC 42 CATCCAGC
EIF3S10 Eukaryotic translation 
initiation factor 3, subunit 
10 theta
NM_003750.1 AGTAGAGCGCCTGTACCATGA GCGTGTATTGGAGGCAGAAT 61 TTGCCCAG
GUSB b-glucuronidase NM_000181.1 CGCCCTGCCTATCTGTATTC TCCCCACAGGGAGTGTGTAG 57 CTGGGGCC
UBE2D2 Ubiquitin-conjugating 
enzyme E2D 2
NM_003339.2 AATGGCAGCATTTGTCTTGA CACAACAGAGAACAGATGGACAA 67 CTCCAGCA
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To determine between-group differences, we used 
Mann-Whitney nonparametric test. Differences were 
considered significant at p < 0.05. The fold change was 
calculated by dividing medians of expression.
Results
The results of the analysis for each gene: PRL, GH, 
POMC, TSHb, LHb, FSHb and CGA were presented in 
the form of a report showing the raw data: Ct value 
and the relative of the template, which was read from 
the standard curve. The expression of the investigated 
genes was normalised with relation to a reference in-
dex, obtained by calculation of the geometric mean of 
expression of reference genes: ACTB, EIF3S10, ATP6V1E, 
UBE2D2, B2M, and GUS B. The comparison was per-
formed in particular types of pituitary adenomas: FA/ 
/null, PRL+/GH+, PRL+/null, GH+/null, GH+/ACTH+, 
ACTH+/null, LH+/FSH+, LH+/null and FSH+/null. 
We observed significant differences in gene expression 
in particular types of pituitary adenomas (Table II).
PRL gene
The highest expression of PRL gene was observed in 
pituitary adenomas, which were GH+ in the IHC study; 
PRL+ adenomas were in the third place. We observed 
also that expression of PRL gene was the lowest in 
FSH+ adenomas. When we compared all functional 
adenomas (FA) with immunohistochemically-negative 
adenomas (null) PRL gene showed 3.5x higher expres-
sion in FA; however, the difference was not significant.
GH gene
In a comparison of GH+ and other groups of functional 
adenomas we observed significantly higher expression 
of GH gene in the GH+/PRL+ comparison (3674×≠; 
p = 0.005) (Fig. 1A). Expression of GH gene was also 
significantly higher when we compared immunohis-
tochemically-negative adenomas (null) with GH+ 
adenomas (23618×≠; p = 0.002) (Fig. 1B) and PRL+ 
adenomas (6×≠; p = 0.015) (Fig. 1C).
POMC gene
The expression of POMC gene was similarly low in all 
pituitary groups except adenomas, which were ACTH+ 
in the IHC study. Significant differences were observed 
in the comparison of ACTH+ and null adenomas 
(32×≠; p = 0.01) (Fig. 2).
TSHb gene
For TSHb gene we observed higher expression in TSH+ 
adenomas than PRL+, GH+, and FSH+. What is 
interesting is that we observed also an increase in TSHb 
gene expression in LH+ adenomas, and the difference 
between TSH+ and LH+ was not significant. Analysis 
of particular groups of adenomas showed significant 
differences only for comparison of TSH+/null (3×≠; 
p = 0.04) (Fig. 3A) and LH+/null (3.25×≠; p = 0.038) 
(Fig. 3B).
LHb gene
The highest expression of LHb gene was observed 
in LH+ adenomas, and in second place were PRL+ 
adenomas. However, our analysis did not show signifi-
cant differences between LH+ and FSH+ adenomas.
FSHb gene
In the comparison of all groups of pituitary adenomas 
the highest expression of FSHb gene was noticed in 
FSH+ adenomas. The difference of expression level was 
significant only for comparison of FSH+/null (28×≠; 
p = 0.006) (Fig. 4).
CGA gene
In the case of CGA gene the highest expression was 
observed in LH+ adenomas, while the lowest was 
in GH+ adenomas. Expression of CGA gene was on 
a similar level in TSH+ and FSH+ adenomas. We did not 
observe significant differences in comparisons of: FSH+ 
and LH+ adenomas, FSH+ and TSH+ adenomas, and 
TSH+ and LH+ adenomas. Gene CGA was significantly 
overexpressed in LH+ adenomas in comparison to null 
adenomas (13×≠; p = 0.0008) (Fig. 5).
Discussion
One of the first results of a microarray study in 
pituitary adenomas was published by Evans et al. in 
2001 [8]. In recent years researchers have used this 
high-throughput technique to compare gene expres-
sion between normal tissues and pituitary adenomas, 
and identified many genes associated with particular 
tumour types [9–15].
Our study was intended to evaluate gene expression 
of pituitary hormone and their precursor genes: PRL, 
GH, POMC, TSHb, FSHb, LHb, and CGA in particular 
types of functional and non-functional pituitary ad-
enomas using QPCR technique.
In most cases we obtained results that were consist-
ent with the secretory status of the adenoma subtype. 
However, comparison of our results with other pub-
lished studies is rather difficult because of the methods 
we used. Generally, pituitary adenomas are classified 
in immunohistochemical tests [16, 17], and molecular 
techniques are not used. We found confirmation of our 
results in a studies by Evans at al. [8] and Morris et al. 
[9], in which gene expression profile was analysed by 
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Table II. The expression of investigated genes in different types of pituitary adenomas 
Tabela II. Wartości względne odzwierciedlające ekspresję genów badanych w poszczególnych typach gruczolaków przysadki
Type of pituitary 
adenomas
Number Gene expression Descriptive statistic Comparison of each 
class to  null (p level  
is given if significant)
Median Quartile 1 Quartile 3 Skewness Kurtosis
PRL  
GH 13 0.427 0.005 6.012 3.479 12.317 ns
PRL 26 0.273 0.015 55.374 1.883 3.158 ns
LH 11 0.393 0.024 0.899 1.262 0.933 ns
FSH 5 0.088 0.001 1.802 0.548 –2.886 ns
FA* 52 0.125 0.012 6.252 2.837 8.421 ns
NFA* 31 0.087 0.005 0.611 4.436 21.963  
null 15 0.037 0.005 0.611 3.823 14.72
GH  
GH 13 165.332 0.226 216.951 1.667 2.778 0.002
PRL 26 0.045 0.012 0.376 3.145 9.623 0.015
LH 11 0.018 0.005 0.381 2.82 8.264 ns
FSH 5 0.749 0.001 0.749 –0.073 –2.826 ns
FA* 52 0.176 0.012 41.389 2.81 8.078 0.001
NFA* 32 0.021 0.002 0.475 3.822 16.585
null 16 0.007 0.001 0.475 3.256 11.255
POMC  
ACTH 8 0.097 0.062 10.658 1.145 –0.631 0.01
GH 13 0.001 0.0004 0.018 2.113 4.924 ns
PRL 26 0.002 0.001 0.013 5.068 25.776 ns
LH 11 0.002 0.001 0.014 3.262 10.724 ns
FSH 5 0.003 0.003 0.009 0.607 –2.697 ns
FA* 52 0.009 0.001 0.034 4.351 18.675 ns
NFA* 32 0.003 0.001 0.01 2.943 8.471
null 16 0.003 0 0.01 2.222 4.234
TSH B  
TSH 5 1.584 0.798 5.456 0.616 –2.595 0.04
GH 13 0.786 0.103 1.522 0.474 –1.336 ns
PRL 14 0.599 0.135 1.447 2.581 6.441 ns
LH 11 1.716 0.475 3.201 1.793 2.212 0.038
FSH 5 1.482 1.006 1.776 –0.635 0.535 ns
FA* 50 0.759 0.128 1.569 2.719 7.693 ns
NFA* 32 0.786 0.411 1.66 3.432 11.964
null 16 0.528 0.245 1.66 1.18 2.188
LH B  
GH 12 0.007 0.002 1.371 2.456 6.170 ns
PRL 22 0.264 0.01 0.915 2.569 7.109 ns
LH 11 0.422 0.007 2.213 2.074 4.856 ns
FSH 5 0.03 0.03 3.815 0.278 –1.749 ns
FA* 46 0.038 0.004 0.64 2.962 8.922 ns
NFA* 32 0.095 0.005 1.77 1.881 2.979
null 16 0.055 0.004 1.77 3.127 10.536
Æ
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(normal pituitary, PRL+, GH+, and ACTH+). For 
PRL gene these analyses showed, in comparison to 
normal pituitary, overexpression in PRL+ adenomas 
(fold change 2.9×; 3.7× respectively), underexpres-
sion in non-functional adenomas (fold change 31.3×; 
> 10× respectively), ACTH+ adenomas (fold change 
10.7×; 2.4× respectively), and in GH+ adenomas 
(fold change 2.2×; 4.5× respectively). In our study 
PRL gene showed the highest expression in pituitary 
adenomas that secreted GH, and prolactinomas were 
in the third place. Our comparison of all functional and 
immunohistochemically-negative adenomas showed 
3.5× higher expression  in FA; however, the difference 
was not significant. The results indicate that PRL gene 
is not a characteristic gene for prolactinomas. 
In the case of GH gene we observed higher expres-
sion in GH+ adenomas in comparison to other groups 
of pituitary adenomas. According to our expectations, 
this gene was significantly overexpressed in GH+ 
adenomas when we compared it with PRL+ (3674×) and 
also with immunohistochemically-negative adenomas 
(23618×). Our results are consistent with the results of 
Evans and Morris, who showed overexpression of GH 
gene in somatotropinomas in comparison to normal 
pituitary (2× and 9.6×, respectively) and underexpression 
in prolactinomas (2.2× and 10×, respectively), cortico-
tropinomas (2.8× and > 10×, respectively), and non-
functional adenomas (31.3× and > 10×, respectively). 
Our obtained results confirm that GH is a characteristic 
gene for GH+ adenomas. We drew a similar conclusion 
for POMC gene, expression of which was low in all 
pituitary adenomas except adrenocorticotropinomas. 
We observed the same trend in the study of Morris. 
POMC was the most highly expressed gene in ACTH+ 
adenomas, whereas its expression was lower in GH+ 
(> 10×), PRL+ (> 10×), and non-functional adenomas 
(> 10×). Based on the results, we confirm that POMC is 
a characteristic gene for adrenocorticotropinomas. 
Another gene which we analysed was TSHb encod-
ing b subunit of TSH. We showed that its expression was 
higher in TSH+ adenomas than in PRL+, GH+, and 
FSH+ adenomas, but we did not observe statistically 
significant differences between groups of functional 
adenomas. When we compared particular groups of 
pituitary adenomas with null adenomas we observed 
significantly higher expression of TSHb gene in TSH+ 
(3×) and LH+ (3.25×) adenomas. We noticed a similar 
direction in the above-mentioned studies [8,9]. TSHb 
Table II cd. The expression of investigated genes in different types of pituitary adenomas 
Tabela II cd. Wartości względne odzwierciedlające ekspresję genów badanych w poszczególnych typach gruczolaków przysadki
Type of pituitary 
adenomas
Number Gene expression Descriptive statistic Comparison of each 
class to  null (p level  
is given if significant)
Median Quartile 1 Quartile 3 Skewness Kurtosis
FHS B  
GH 12 0.006 0.0002 0.426 2.055 3.151 ns
PRL 20 0.31 0.031 2.915 4.472 20 ns
LH 11 1.11 0.111 3.235 0.524 –1.394 ns
FSH 5 2.525 2.621 7.131 –0.319 –2.959 0,006
FA* 42 0.072 0.001 0.99 6.481 42 ns
NFA* 31 0.305 0.073 3.553 0.931 –0.176
null 15 0.089 0.013 3.553 1.227 –0.176
CGA
GH 16 0.078 0.012 0.646 1.517 0.865 ns
PRL 26 0.227 0.052 1.138 2.776 9.119 ns
TSH 5 0.98 0.008 1.806 0.608 –1.072 ns
LH 11 3.577 0.929 7.219 1.004 –0.139 0,0008
FSH 5 0.88 0.36 0.948 1.938 3.989 ns
FA* 52 0.166 0.029 1.377 2.662 7.961 ns
NFA* 31 0.31 0.18 1.727 2.414 5.44
null 15 0.271 0.117 1.727 1.366 2.912
FA — functional adenomas, null— immunohistochemically-negative adenomas, GH — somatotropinomas, PRL — prolactinomas, ACTH — corticotropinomas,  
TSH — thyrotropic adenomas; LH, FSH — gonadotropic adenomas, NFA — common group of immunohistochemistry negative adenomas and gonadotropic adenomas,  
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Figure 1. Comparison of GH expression in: A. GH+ to PRL+ 
pituitary adenomas, (U Mann Whitney test, p = 0.005); B. GH+ 
to IHC negative (null) pituitary adenomas, (U Mann Whitney test, 
p = 0.002); C. PRL+ to IHC negative (null) pituitary adenomas, 
(U Mann Whitney test, p = 0.015)
Rycina 1. Porównanie ekspresji genu GH w: A. Gruczolakach 
GH+ w porównaniu z gruczolakami PRL+, (test U Manna 
Whitneya, p = 0.005); B. Gruczolakach GH+ w porównaniu 
z gruczolakami IHC ujemnymi (null) (test U Manna Whitneya, 
p = 0.002); C. Gruczolakach PRL+ w porównaniu z gruczolakami 




gene was underexpressed in PRL+ (17.2× and > 10×, 
respectively), GH+ (16.2× and > 10×, respectively), 
and non-functional adenomas (2.4× and >10×, respec-
tively), in comparison to normal pituitary. The next two 
genes are expressed in pituitary adenomas that are clini-
cally non-functional, but they can produce glycoprotein 
hormones: LH or FSH. According to our expectations, 
expression of LHb and FSHb genes was the highest, 
respectively, in LH+ and FSH+ adenomas; we noticed 
lower expression of these genes in PRL+, GH+, and 
immunohistochemically-negative adenomas. We found 
similar results in the studies by Evans et al. and Morris et 
al. Expression of LHb gene was lower in PRL+ (4× and 
2×, respectively), GH+ (4.9× and 8×, respectively), and 
in non-functional adenomas (6.2× and 7.7×, respec-
tively). FSHb gene was underexpressed in PRL+ (10.2× 
Figure 2. Comparison of POMC expression in ACTH+ to IHC 
negative (null) pituitary adenomas, (U Mann Whitney test, 
p = 0.01)
Rycina 2. Porównanie ekspresji genu POMC w gruczolakach 
ACTH+ w porównaniu z gruczolakami IHC ujemnymi (null), 
(test U Manna Whitneya, p = 0.01)
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Figure 3. Comparison of TSHb expression in: A. TSH+ to IHC negative (null) pituitary adenomas, (U Mann Whitney test, p = 0.04); 
B. LH+ to IHC negative (null) pituitary adenomas, (U Mann Whitney test, p = 0.038) 
Rycina 3. Porównanie ekspresji genu TSHb w: A. Gruczolakach TSH+ w porównaniu z gruczolakami IHC ujemnymi (null), (test 
U Manna Whitneya, p = 0.04); B. Gruczolakach LH+ w porównaniu z gruczolakami IHC ujemnymi (null), (test U Manna Whitneya, 
p = 0.038)
Figure 4. Comparison of FSHb expression in FSH+ to IHC 
negative (null) pituitary adenomas, (U Mann Whitney test, 
p = 0.006) 
Rycina 4. Porównanie ekspresji genu FSHb w gruczolakach 
FSH+ w porównaniu z gruczolakami IHC ujemnymi (null), (test 
U Manna Whitneya, p = 0.006)
Figure 5. Comparison of CGA expression in LH+ to IHC negative 
(null) pituitary adenomas, (U Mann Whitney test, p = 0.0008)
Rycina 5. Porównanie ekspresji genu CGA w gruczolakach LH+ 
w porównaniu z gruczolakami IHC ujemnymi (null), (test 
U Mann Whitneya, p = 0.0008) 
and 2×, respectively), GH+ (23× and 3.6×, respectively), 
and in non-functional adenomas (2.4× [8]). Although the 
differences in LHb and FSHb gene expression were notice-
able between particular types of pituitary adenomas our 
analysis did not show statistically significant differences 
between LH+ and FSH+ adenomas.
The last CGA gene codes alpha subunit of glyco-
protein hormones which is common for FSH, LH, 
and TSH. In our study we did not observe significant 
differences in CGA expression in particular types 
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Conclusions
Our study showed that GH is a characteristic gene for 
somatotropinomas. We drew a similar conclusion for 
POMC gene and adrenocorticotropinomas.
However, the results which we obtained for PRL, 
TSHb, LHb, FSHb and CGA genes indicate that evalua-
tion of gene expression is not sufficient for classification 
of particular subtypes of pituitary adenomas. 
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